Ocular Therapeutix(US:OCUL) ZACKS·2026-02-05 14:11分组1 - Ocular Therapeutix reported a quarterly loss of $0.29 per share, better than the Zacks Consensus Estimate of a loss of $0.33, representing an earnings surprise of +12.65% [1] - The company posted revenues of $13.25 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 12.22%, and down from $17.08 million year-over-year [2] - Ocular Therapeutix shares have declined approximately 29.6% since the beginning of the year, contrasting with the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.33 on revenues of $13.32 million, and for the current fiscal year, it is -$1.39 on revenues of $59.47 million [7] - The Zacks Industry Rank for Medical - Drugs is in the bottom 36% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]